ObesityNCT07472608
Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)
An observational study of Obesity and Metabolic Abnormalities, run by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval at 1 site in Canada.
Trial summary
Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Metabolic Abnormalities, Health
- What is being tested?
- Behavioral and Pharmacological Treatments
- How many people
- 25,000 participants
- Where
- 1 siteCanada
- Study dates
- 1 Jun 2026to Jun 2051
- How long will I take part?
- 25 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.
To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:
- Be over 18 years of age
- Meet at least one of the following five criteria:
- Body mass index ≥30 kg/m2 with or without comorbidities (preclinical or clinical obesity);
- Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);
- History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;
- History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;
- Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Fannie Lajeunesse-Trempe, MD PhD FRCPC contact
Canada1 site
Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, G1V 4G5
Audrey St-Laurent, PhD, 418-656-8711 ext. 2681, audrey.st-laurent@criucpq.ulaval.ca
Fannie Lajeunesse-Trempe, MD PhD FRCPC
About this study
Official title: Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)
Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.
A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.
Read more
This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:
- To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
- To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
- To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
- To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
- To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.
- Conditions
- Obesity, Metabolic Abnormalities, Health
- Being tested
- Behavioral and Pharmacological Treatments
- Keywords
- Biobank, Clinical data, Radiological data, Genetic data, Biochemical data, Cardiac data, Blood samples, Prospective patient registry, Bariatric medicine, Health, Obesity medicine
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral and Pharmacological TreatmentsOther
Behavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs.
| Study group | Role | What they receive |
|---|---|---|
| Obesity medicine cohort | This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval Receives: Other: Behavioral and Pharmacological Treatments |
What is being measured
The primary outcome is the main question the study is designed to answer.
Success or failure of obesity medicine interventions
- Anthropometric Parameters: weight and height combined to obtain BMI (kg/m^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis
- Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available)
- Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts
- Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts
- Mental Health Parameters: As recorded in medical charts
Measured: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start1 Jun 2026 (estimated)
- Primary completionJun 2051 (estimated)
- Study completionJun 2051 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 25,000 participants (estimated)
- Target duration
- 25 Years
Sponsor and investigators
- Lead sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Sponsor type
- University, hospital or other
- Collaborators
- Eli Lilly and Company
- Responsible party
- Principal investigator, Fannie Lajeunesse-Trempe, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07472608
- Sponsor's protocol ID
- 2025-4343
- Status last verified
- Mar 2026
- First submitted
- 27 Feb 2026
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)
- ClinicalTrials.gov ID
- NCT07472608
- Acronym / sponsor ID
- 2025-4343
- Conditions
- Obesity, Metabolic Abnormalities, Health
- Keywords
- Biobank, Clinical data, Radiological data, Genetic data, Biochemical data, Cardiac data, Blood samples, Prospective patient registry
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 25,000 participants (estimated)
- Lead sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University LavalUniversity, hospital or other
- Collaborators
- Eli Lilly and Company
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- Jun 2051 (estimated)
- Study completion
- Jun 2051 (estimated)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.
A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.
This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:
- To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
- To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
- To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
- To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
- To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 25 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Obesity medicine cohort | – | Other: Behavioral and Pharmacological TreatmentsThis cohort includes patients followed in bariatric medicine at IUCPQ-ULaval |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral and Pharmacological TreatmentsBehavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs. | Other | Obesity medicine cohort |
Primary outcome
Success or failure of obesity medicine interventions
Time frame: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another
1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis 2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available) 3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts 4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts 5. Mental Health Parameters: As recorded in medical charts
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Fannie Lajeunesse-Trempe, MD PhD FRCPC contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Metabolic Abnormalities, run by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Audrey St-Laurent, PhD (418-656-8711 ext. 2681, audrey.st-laurent@criucpq.ulaval.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Success or failure of obesity medicine interventions (time frame: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.